Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy

Abstract

Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had ≥1 prior systemic therapy. Here, we present a subanalysis of two phase-2 trials (NCT00106431, NCT00007345) of romidepsin in patients with CTCL who had prior treatment with systemic chemotherapy. Patients with prior chemotherapy were able to achieve durable responses to romidepsin, and response rates were similar to those in patients who were chemotherapy naïve. Overall, no new safety signals emerged in patients who had received prior chemotherapy. The data presented here suggest that romidepsin is safe and effective in patients with CTCL who received prior systemic chemotherapy.

Keywords:

• Cutaneous T-cell lymphoma
• romidepsin
• chemotherapy

Acknowledgments

The authors would like to acknowledge Maureen Edgerly. The authors take full responsibility for the content of this manuscript, but thank William Ho, PhD (MediTech Media, Ltd), for providing medical editorial assistance. Financial support for medical editorial assistance was provided by Celgene Corporation.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1361022.

Additional information

Funding

Celgene Corporation10.13039/100006436

M. Duvic reports MD Anderson Cancer Center received support for the conduct of the original study. S. Bates reports grants from Celgene Inc., during the conduct of the study; other from Celgene, outside the submitted work; has a patent #: US 8,957,027 issued, a patent #: US 8,637,888 issued, and a patent US 13/722,995 pending. J. Becker reports non-financial support from Gloucester Pharmaceuticals, during the conduct of the study; grants and personal fees from BMS; grant, personal fees, non-financial support and other from Merck Serono; grants and personal fees from Amgen; personal fees from Takeda; personal fees from Novartis, outside the submitted work. W. McCulloch reports personal fees from Celgene Inc., during the conduct of the study; other from Celgene Inc., outside the submitted work; has a patent WO2007/145704 pending. J. Waksman reports personal fees from Celgene Inc., during the conduct of the study.